Maccura Biotechnology Co.Ltd (300463.SZ)
CNY 13.88
(0.51%)
CNY 13.88
(0.51%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 665.16 Million CNY | -5.14% |
| 2022 | 701.21 Million CNY | -37.14% |
| 2021 | 1.11 Billion CNY | -15.58% |
| 2020 | 1.32 Billion CNY | -12.22% |
| 2019 | 1.5 Billion CNY | 26.09% |
| 2018 | 1.19 Billion CNY | 78.3% |
| 2017 | 669.53 Million CNY | 236.88% |
| 2016 | 198.74 Million CNY | 0.25% |
| 2015 | 198.24 Million CNY | -31.8% |
| 2014 | 290.67 Million CNY | 122.39% |
| 2013 | 130.7 Million CNY | 23.24% |
| 2012 | 106.05 Million CNY | -1.81% |
| 2011 | 108 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 734.05 Million CNY | 10.36% |
| 2024 Q3 | 483.38 Million CNY | -42.27% |
| 2024 Q2 | 851.76 Million CNY | 16.04% |
| 2023 Q4 | 665.16 Million CNY | -17.89% |
| 2023 Q3 | 810.08 Million CNY | -13.73% |
| 2023 Q1 | 735.7 Million CNY | 4.92% |
| 2023 FY | 665.16 Million CNY | -5.14% |
| 2023 Q2 | 939.05 Million CNY | 27.64% |
| 2022 Q4 | 701.21 Million CNY | -19.82% |
| 2022 Q3 | 874.57 Million CNY | -7.04% |
| 2022 Q2 | 940.8 Million CNY | 19.43% |
| 2022 FY | 701.21 Million CNY | -37.14% |
| 2022 Q1 | 787.74 Million CNY | -29.38% |
| 2021 FY | 1.11 Billion CNY | -15.58% |
| 2021 Q4 | 1.11 Billion CNY | -19.39% |
| 2021 Q1 | 1.43 Billion CNY | 8.64% |
| 2021 Q2 | 1.62 Billion CNY | 13.29% |
| 2021 Q3 | 1.38 Billion CNY | -14.91% |
| 2020 Q4 | 1.32 Billion CNY | -15.95% |
| 2020 FY | 1.32 Billion CNY | -12.22% |
| 2020 Q2 | 1.6 Billion CNY | 5.54% |
| 2020 Q1 | 1.52 Billion CNY | 1.22% |
| 2020 Q3 | 1.57 Billion CNY | -2.24% |
| 2019 Q4 | 1.5 Billion CNY | 1.95% |
| 2019 Q3 | 1.47 Billion CNY | 7.67% |
| 2019 Q2 | 1.37 Billion CNY | 10.72% |
| 2019 Q1 | 1.23 Billion CNY | 3.75% |
| 2019 FY | 1.5 Billion CNY | 26.09% |
| 2018 FY | 1.19 Billion CNY | 78.3% |
| 2018 Q2 | 937.08 Million CNY | 8.91% |
| 2018 Q1 | 860.39 Million CNY | 28.51% |
| 2018 Q4 | 1.19 Billion CNY | 8.5% |
| 2018 Q3 | 1.1 Billion CNY | 17.42% |
| 2017 Q1 | 182.83 Million CNY | -8.01% |
| 2017 FY | 669.53 Million CNY | 236.88% |
| 2017 Q4 | 669.53 Million CNY | 15.66% |
| 2017 Q3 | 578.85 Million CNY | 51.2% |
| 2017 Q2 | 382.85 Million CNY | 109.4% |
| 2016 FY | 198.74 Million CNY | 0.25% |
| 2016 Q4 | 198.74 Million CNY | -30.72% |
| 2016 Q3 | 286.85 Million CNY | 12.7% |
| 2016 Q2 | 254.54 Million CNY | 48.88% |
| 2016 Q1 | 170.97 Million CNY | -13.75% |
| 2015 Q1 | 348.65 Million CNY | 19.95% |
| 2015 FY | 198.24 Million CNY | -31.8% |
| 2015 Q4 | 198.24 Million CNY | -17.43% |
| 2015 Q3 | 240.08 Million CNY | -28.8% |
| 2015 Q2 | 337.19 Million CNY | -3.29% |
| 2014 FY | 290.67 Million CNY | 122.39% |
| 2014 Q4 | 290.67 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2013 FY | 130.7 Million CNY | 23.24% |
| 2012 FY | 106.05 Million CNY | -1.81% |
| 2011 FY | 108 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.29 Billion CNY | 84.501% |
| Hangzhou Tigermed Consulting Co., Ltd. | 3.34 Billion CNY | 80.124% |
| Dirui Industrial Co.,Ltd. | 714.1 Million CNY | 6.854% |
| Beijing Strong Biotechnologies, Inc. | 1.13 Billion CNY | 41.428% |
| Medicalsystem Biotechnology Co., Ltd. | 108.17 Million CNY | -514.917% |
| Guangzhou Wondfo Biotech Co.,Ltd | 599.53 Million CNY | -10.946% |
| Guangdong Hybribio Biotech Co.,Ltd. | 56.65 Million CNY | -1074.113% |
| BGI Genomics Co., Ltd. | 1.09 Billion CNY | 39.332% |
| Amoy Diagnostics Co., Ltd. | 108.34 Million CNY | -513.924% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 374.62 Million CNY | -77.556% |